290 related articles for article (PubMed ID: 33318017)
1.
Papp-Wallace KM; Shapiro AB; Becka SA; Zeiser ET; LiPuma JJ; Lane DJ; Panchal RG; Mueller JP; O'Donnell JP; Miller AA
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318017
[TBL] [Abstract][Full Text] [Related]
2. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant
Zeiser ET; Becka SA; Wilson BM; Barnes MD; LiPuma JJ; Papp-Wallace KM
J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167848
[TBL] [Abstract][Full Text] [Related]
3. Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting
McLeod SM; O'Donnell JP; Narayanan N; Mills JP; Kaye KS
Future Microbiol; 2024; 19(7):563-576. PubMed ID: 38426849
[TBL] [Abstract][Full Text] [Related]
4.
McLeod SM; Moussa SH; Hackel MA; Miller AA
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988095
[No Abstract] [Full Text] [Related]
5. The Class A β-Lactamase Produced by
Becka SA; Zeiser ET; LiPuma JJ; Papp-Wallace KM
Antibiotics (Basel); 2022 May; 11(5):. PubMed ID: 35625319
[TBL] [Abstract][Full Text] [Related]
6. Assessing the Potency of β-Lactamase Inhibitors with Diverse Inactivation Mechanisms against the PenA1 Carbapenemase from
Nukaga M; Yoon MJ; Taracilia MA; Hoshino T; Becka SA; Zeiser ET; Johnson JR; Papp-Wallace KM
ACS Infect Dis; 2021 Apr; 7(4):826-837. PubMed ID: 33723985
[No Abstract] [Full Text] [Related]
7. Antibiotic resistance in Burkholderia species.
Rhodes KA; Schweizer HP
Drug Resist Updat; 2016 Sep; 28():82-90. PubMed ID: 27620956
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis.
Sagan O; Yakubsevitch R; Yanev K; Fomkin R; Stone E; Hines D; O'Donnell J; Miller A; Isaacs R; Srinivasan S
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31843995
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance.
Findlay J; Poirel L; Bouvier M; Nordmann P
J Glob Antimicrob Resist; 2022 Sep; 30():445-450. PubMed ID: 35618210
[TBL] [Abstract][Full Text] [Related]
10. Recombinant Salmonella Expressing Burkholderia mallei LPS O Antigen Provides Protection in a Murine Model of Melioidosis and Glanders.
Moustafa DA; Scarff JM; Garcia PP; Cassidy SK; DiGiandomenico A; Waag DM; Inzana TJ; Goldberg JB
PLoS One; 2015; 10(7):e0132032. PubMed ID: 26148026
[TBL] [Abstract][Full Text] [Related]
11. Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli.
Becka SA; Zeiser ET; LiPuma JJ; Papp-Wallace KM
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0133221. PubMed ID: 34370574
[TBL] [Abstract][Full Text] [Related]
12. Sulbactam-durlobactam: A novel β-lactam-β-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections.
El-Ghali A; Kunz Coyne AJ; Caniff K; Bleick C; Rybak MJ
Pharmacotherapy; 2023 Jun; 43(6):502-513. PubMed ID: 37052117
[TBL] [Abstract][Full Text] [Related]
13. Burkholderia mallei and Burkholderia pseudomallei: the causative micro-organisms of glanders and melioidosis.
Gilad J
Recent Pat Antiinfect Drug Discov; 2007 Nov; 2(3):233-41. PubMed ID: 18221181
[TBL] [Abstract][Full Text] [Related]
14. Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant
August B; Matlob A; Kale-Pradhan PB
Ann Pharmacother; 2024 Jul; 58(7):735-741. PubMed ID: 37817550
[TBL] [Abstract][Full Text] [Related]
15. A conserved active site PenA β-lactamase Ambler motif specific for Burkholderia pseudomallei/B. mallei is likely responsible for intrinsic amoxicillin-clavulanic acid sensitivity and facilitates a simple diagnostic PCR assay for melioidosis.
Somprasong N; Hagen JP; Sahl JW; Webb JR; Hall CM; Currie BJ; Wagner DM; Keim P; Schweizer HP
Int J Antimicrob Agents; 2023 Mar; 61(3):106714. PubMed ID: 36640845
[TBL] [Abstract][Full Text] [Related]
16. Burkholderia ubonensis Meropenem Resistance: Insights into Distinct Properties of Class A β-Lactamases in Burkholderia cepacia Complex and Burkholderia pseudomallei Complex Bacteria.
Somprasong N; Hall CM; Webb JR; Sahl JW; Wagner DM; Keim P; Currie BJ; Schweizer HP
mBio; 2020 Apr; 11(2):. PubMed ID: 32291300
[No Abstract] [Full Text] [Related]
17. Burkholderia vaccines: are we moving forward?
Choh LC; Ong GH; Vellasamy KM; Kalaiselvam K; Kang WT; Al-Maleki AR; Mariappan V; Vadivelu J
Front Cell Infect Microbiol; 2013; 3():5. PubMed ID: 23386999
[TBL] [Abstract][Full Text] [Related]
18. Protective efficacy of heat-inactivated B. thailandensis, B. mallei or B. pseudomallei against experimental melioidosis and glanders.
Sarkar-Tyson M; Smither SJ; Harding SV; Atkins TP; Titball RW
Vaccine; 2009 Jul; 27(33):4447-51. PubMed ID: 19490962
[TBL] [Abstract][Full Text] [Related]
19. Burkholderia Hep_Hag autotransporter (BuHA) proteins elicit a strong antibody response during experimental glanders but not human melioidosis.
Tiyawisutsri R; Holden MT; Tumapa S; Rengpipat S; Clarke SR; Foster SJ; Nierman WC; Day NP; Peacock SJ
BMC Microbiol; 2007 Mar; 7():19. PubMed ID: 17362501
[TBL] [Abstract][Full Text] [Related]
20. Use of a safe, reproducible, and rapid aerosol delivery method to study infection by Burkholderia pseudomallei and Burkholderia mallei in mice.
Lafontaine ER; Zimmerman SM; Shaffer TL; Michel F; Gao X; Hogan RJ
PLoS One; 2013; 8(10):e76804. PubMed ID: 24098563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
